RARE•benzinga•
Ultragenyx Doses First Patient In Pivotal Phase 3 Aspire Study Evaluating GTX-102 In Angelman Syndrome
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on December 19, 2024 by benzinga